Leerink Starts Larimar Therapeutics (LRMR) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/21/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
Tweet
Share
E-mailGet Alerts LRMR Hot Sheet
Price: $2.42 -0.82%
Rating Summary:
12 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 31
Rating Summary:
12 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 17 | New: 31
Join SI Premium – FREE
Leerink analyst Joseph Schwartz initiates coverage on Larimar Therapeutics (NASDAQ: LRMR) with a Outperform rating and a price target of $13.00.
For an analyst ratings summary and ratings history on Larimar Therapeutics click here. For more ratings news on Larimar Therapeutics click here.
Shares of Larimar Therapeutics closed at $3.92 yesterday.
You May Also Be Interested In
- Guggenheim Starts Kazia Therapeutics (KZIA) at Buy
- TD Cowen Starts CenterPoint Energy (CNP) at Buy
- Baird Starts Kardigan Inc (KARD) at Outperform, PT $43
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
